Big Biotech Emerges as Late-Stage Licensee
The sheer size of today's Big Pharmas has created a problem when it comes to licensing late-stage products; many of those available simply don't have large enough revenue projections to significantly contribute to the Big Pharmas' earnings. But larger biotechs, which don't necessarily need blockbusters to grow earnings, seem to have begun to fill the gap.
You may also be interested in...
Are biotechs abandoning drug discovery-based business models in favor of in-licensing-based development and marketing strategies? In both annual count and, more dramatically, dollar volume, deals in which biotechs in-license late-stage products-from other biotechs, or from larger pharmaceutical companies-have spiked over the past two years.
Pharma industry critics herald the agreement for allowing many manufacturers around the world to make the COVID-19 therapeutic and for its transparency. If Merck can do it, they ask, why can’t other companies?